Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 18.0% in April

Lucid Diagnostics Inc. (NASDAQ:LUCD) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 361,400 shares, a decline of 18.0% from the March 31st total of 441,000 shares. Currently, 2.5% of the company’s shares are short sold. Based on an average daily volume of 164,900 shares, the days-to-cover ratio is presently 2.2 days.

Lucid Diagnostics Price Performance

NASDAQ LUCD traded up $0.01 during trading hours on Friday, hitting $0.68. The company’s stock had a trading volume of 123,806 shares, compared to its average volume of 180,015. The company’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $1.24. Lucid Diagnostics has a 12 month low of $0.63 and a 12 month high of $1.85.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Tuesday, March 26th. The company reported ($0.26) earnings per share (EPS) for the quarter. The business had revenue of $1.04 million during the quarter. Lucid Diagnostics had a negative return on equity of 901.79% and a negative net margin of 2,169.07%. During the same quarter last year, the firm posted ($0.22) earnings per share. On average, sell-side analysts forecast that Lucid Diagnostics will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LUCD shares. Needham & Company LLC restated a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a research note on Friday, April 12th. Cantor Fitzgerald dropped their target price on shares of Lucid Diagnostics from $3.80 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 27th.

About Lucid Diagnostics

Lucid Diagnostics Inc, a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.